Lipid profile and response to statin therapy in patients with hypopituitarism
Authors:
- Graziela RissettiGRGraziela Rissetti
- Débora ZeniDZDébora Zeni
- Bárbara Roberta OngarattiBOBárbara Roberta Ongaratti
- Júlia Fernanda Semmelmann Pereira-LimaJPJúlia Fernanda Semmelmann Pereira-Lima
- Carolina Garcia Soares Leães RechCRCarolina Garcia Soares Leães Rech
- Miriam da Costa OliveiraMOMiriam da Costa Oliveira
Open Access
- 9 October 2020
- journal article
- research article
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 64 (AHEAD) , 673-678
Abstract
Objective: Dyslipidemia is prevalent among patients with hypopituitarism, especially in those with growth hormone (GH) deficiency.This study aimed to evaluate the response to statin therapy among adult patients with dyslipidemia and hypopituitarism. Subjects and methods: A total of 113 patients with hypopituitarism following up at a neuroendocrinology unit were evaluated for serum lipid levels. Dyslipidemia was diagnosed in 72 (63.7%) of these patients. A control group included 57 patients with dyslipidemia and normal pituitary function. The distribution of gender, age, weight, and dyslipidemia type was well balanced across both groups, and all participants were treated with simvastatin at doses adjusted to obtain normal lipid levels. Results: Patients with hypopituitarism and dyslipidemia presented deficiency ofTSH (69%), gonadotropins (69%), ACTH (64%), and GH (55%) and had a similar number of deficient pituitary axes compared with patients with hypopituitarism but without dyslipidemia. All patients with dyslipidemia (with and without hypopituitarism) had lipid levels well controlled with doses of simvastatin ranging from 20-40 mg/day. The mean daily dose of simvastatin was not significantly different between patients with and without hypopituitarism (26.7 versus 23.5 mg, p = 0.10). Similarly, no significant variation in simvastatin dose was observed between patients with different causes of hypopituitarism, presence or absence of GH deficiency, number of deficient pituitary axes, prior pituitary radiation therapy or not, and presence or absence of obesity. Conclusions: Patients with GH deficiency without GH replacement showed good response to simvastatin at a mean dose equivalent to that used in individuals with dyslipidemia and normal pituitary function.Keywords
This publication has 23 references indexed in Scilit:
- Metabolic alterations in patients who develop traumatic brain injury (TBI)-induced hypopituitarismGrowth Hormone & IGF Research, 2013
- V Diretriz Brasileira de Dislipidemias e Prevenção da AteroscleroseArquivos Brasileiros de Cardiologia, 2013
- Epidemiology, mortality rate and survival in a homogeneous population of hypopituitary patientsClinical Endocrinology, 2012
- Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysisEuropean Journal of Endocrinology, 2011
- Prevalência de dislipidemia em indivíduos fisicamente ativos durante a infância, adolescência e idade adultaArquivos Brasileiros de Cardiologia, 2011
- Radiotherapy for pituitary adenomas: long-term outcome and complicationsRadiation Oncology Journal, 2011
- Prevalência de excesso de peso e obesidade e fatores associados, Brasil, 2006Revista de Saúde Pública, 2009
- Growth hormone (GH) replacement decreases serum total and LDL‐cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapyClinical Endocrinology, 2007
- Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern SpainClinical Endocrinology, 2001
- Increased cerebrovascular mortality in patients with hypopituitarismClinical Endocrinology, 1997